CN Patent

CN102046156B — 药物组合物271

Assigned to AstraZeneca AB · Expires 2014-12-17 · 11y expired

What this patent protects

本发明涉及含有6-(4-溴-2-氯-苯基氨基)-7-氟-3-甲基-3H-苯并咪唑-5-甲酸(2-羟基-乙氧基)-酰胺的硫酸氢盐及其溶剂合物、结晶形式和无定形形式的药物组合物，涉及所述组合物作为药物的用途，和涉及制备所述组合物的方法。

USPTO Abstract

本发明涉及含有6-(4-溴-2-氯-苯基氨基)-7-氟-3-甲基-3H-苯并咪唑-5-甲酸(2-羟基-乙氧基)-酰胺的硫酸氢盐及其溶剂合物、结晶形式和无定形形式的药物组合物，涉及所述组合物作为药物的用途，和涉及制备所述组合物的方法。

Drugs covered by this patent

selumetinib-sulfate (SELUMETINIB SULFATE)

Patent Metadata

Patent number: CN102046156B
Jurisdiction: CN
Classification: —
Expires: 2014-12-17
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.